GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
GH Research PLC (Nasdaq: GHRS) has reported its financial results for the year ending December 31, 2022, with a net loss of $22.5 million ($0.432 loss per share), up from a $9.2 million loss in 2021. The company's cash position decreased to $251.7 million from $276.8 million.
Significant business updates include the initiation of a Phase 2b trial for its inhalable mebufotenin product, GH001, targeting treatment-resistant depression. The company also expects to submit an IND for a new aerosol delivery device in Q3 2023 and has expanded its patent portfolio to 11 families.
- Initiated Phase 2b trial of GH001 in treatment-resistant depression.
- Anticipates IND submission for GH001's new aerosol device in Q3 2023.
- Expanded patent portfolio to 11 families related to mebufotenin.
- Increased net loss to $22.5 million in 2022 from $9.2 million in 2021.
- R&D expenses surged to $20.5 million from $8.6 million year-over-year.
- General and administrative expenses rose to $10.1 million from $6.5 million.
DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave updates on its business.
Business Updates
We are pleased to report that we have recently initiated our multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD) (GH001-TRD-201). GH001 is our proprietary inhalable mebufotenin (5-MeO-DMT) product candidate.
We expect to recruit approximately 80 patients for this trial across several European countries. The primary objective will be to determine the efficacy of our single-day individualized dosing regimen (IDR) of GH001 compared with placebo in improving depressive symptoms as assessed by the mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) at the end of the 7-day double-blind phase. The double-blind phase will be followed by a 6-month open-label extension phase where all patients can receive treatment with the GH001 IDR as-needed, based on the patient’s clinical status. Further trial design details are described in our updated corporate presentation, which is available in the investor section on our website.
Recent Business Highlights
In January 2023, we reported development progress in respect of our proprietary aerosol delivery device and our expectation that we will submit an IND for GH001, delivered with this proprietary device, in the third quarter of 2023. The IND-opening study is expected to be a Phase 1 clinical pharmacology trial in healthy volunteers (GH001-HV-106), designed to support bridging to the clinical data generated with the third-party device we currently use in our clinical trials.
We also reported, in January 2023, the recent initiation of our randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers (GH002-HV-105). GH002 is our mebufotenin (5-MeO-DMT) product candidate formulated for administration via a proprietary intravenous approach. We expect to complete this trial in the fourth quarter of 2023.
Furthermore, we reported the recent expansion of our patent portfolio, to include 11 patent families that relate to various aspects of mebufotenin (5-MeO-DMT) use in a therapeutic context, including but not limited to the use of mebufotenin (5-MeO-DMT) for treatment of various disorders when administered by inhalation, or by nasal, buccal, sublingual, intravenous, intramuscular or subcutaneous routes.
We also announced the selection of mebufotenin as the International Nonproprietary Name (INN) for 5-MeO-DMT by the World Health Organization (WHO) Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations.
Full Year 2022 Financial Highlights
Cash position
Cash, cash equivalents and marketable securities were
Research and development expenses
R&D expenses were
General and administrative expenses
G&A expenses were
Net loss
Net loss was
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
About GH001
Our lead product candidate, GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where
About GH002 and GH003
GH002 is our mebufotenin (5-MeO-DMT) product candidate formulated for administration via a proprietary intravenous approach. GH002 is currently in Phase 1 clinical development. GH003 is our mebufotenin (5-MeO-DMT) product candidate formulated for administration via a proprietary intranasal administration approach. GH003 is currently in preclinical development. We anticipate developing GH002 and GH003 in subpopulations and confined use scenarios within our focus area of psychiatric and neurological disorders.
Forward-Looking Statements
This press release contains statements that are, or may be deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including statements regarding our future results of operations and financial position, cash runway, business strategy, product candidates, proprietary medical devices, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor Relations:
Julie Ryan
GH Research PLC
investors@ghres.com
GH RESEARCH PLC
Consolidated Statement of Comprehensive Income (Unaudited)
(in thousands, except share and per share amounts)
| Year ended December 31, | |||
| 2022 | 2021 | ||
| $’000 | $’000 | ||
| Operating expenses | |||
| Research and development | (20,484) | (8,553) | |
| General and administration | (10,070) | (6,547) | |
| Loss from operations | (30,554) | (15,100) | |
| Net finance income/(expense) | 922 | (9) | |
| Foreign exchange gain | 7,176 | 5,907 | |
| Total finance income | 8,098 | 5,898 | |
| Loss before tax | (22,456) | (9,202) | |
| Tax charge/(credit) | — | — | |
| Loss for the year | (22,456) | (9,202) | |
| Other comprehensive income/(expense) | |||
| Items that may be reclassified to profit or loss | |||
| Fair value movement on marketable securities | 558 | — | |
| Currency translation adjustment | (7,132) | (6,103) | |
| Total comprehensive loss for the year | (29,030) | (15,305) | |
| Attributable to owners: | |||
| Loss for the year | (22,456) | (9,202) | |
| Comprehensive loss for the year | (29,030) | (15,305) | |
| Loss per share | |||
| Basic and diluted loss per share (in USD) | (0.432) | (0.211) | |
GH RESEARCH PLC
Consolidated Balance Sheet (Unaudited)
(in thousands)
At December 31, | |||
| 2022 | 2021 | ||
| $’000 | $’000 | ||
| ASSETS | |||
| Current assets | |||
| Cash and cash equivalents | 165,955 | 276,776 | |
| Other current assets | 2,586 | 3,066 | |
| Total current assets | 168,541 | 279,842 | |
| Non-current assets | |||
| Marketable securities | 85,724 | — | |
| Property, plant and equipment | 97 | 82 | |
| Total non-current assets | 85,821 | 82 | |
| Total assets | 254,362 | 279,924 | |
| LIABILITIES AND EQUITY | |||
| Current liabilities | |||
| Trade payables | 1,868 | 883 | |
| Other current liabilities | 2,678 | 1,866 | |
| Total current liabilities | 4,546 | 2,749 | |
| Total liabilities | 4,546 | 2,749 | |
| Equity attributable to owners | |||
| Share capital | 1,301 | 1,301 | |
| Additional paid-in capital | 291,448 | 291,448 | |
| Other reserves | 2,595 | 366 | |
| Foreign currency translation reserve | (13,035) | (5,903) | |
| Accumulated deficit | (32,493) | (10,037) | |
| Total equity | 249,816 | 277,175 | |
| Total liabilities and equity | 254,362 | 279,924 | |
FAQ
What were GH Research's financial results for 2022?
What is the stock symbol for GH Research?
What clinical trials has GH Research initiated recently?
When does GH Research plan to submit an IND for GH001's new delivery device?
How much cash does GH Research have as of December 31, 2022?
